The first study to use a genome-wide approach reported a significant association between an SNP (rs2268363) in the follicle-stimulating hormone receptor (FSHR) gene and the development of erectile dysfunction after radiotherapy for prostate cancer. This evidence concerns the gene FSHR and Familial prostate cancer.